FXN methylation predicts expression and clinical outcome in Friedreich ataxia

Annals of Neurology

Volumn 71, Issue 4, 2012, Pages 487-497

  Evans Galea, Marguerite V ^a,b   Carrodus, Nissa ^a,l   Rowley, Simone M ^a,m   Corben, Louise A ^a,c   Tai, Geneieve ^a   Saffery, Richard ^b,d   Galati, John C ^d   Wong, Nicholas C ^b,d   Craig, Jeffrey M ^b,d   Lynch, David R ^e   Regner, Sean R ^e   Brocht, Alicia F D ^f   Perlman, Susan L ^g   Bushara, Khalaf O ^h   Gomez, Christopher M ⁱ   Wilmot, George R ^j   Li, Lingli ^a,n   Varley, Elizabeth ^a,d   Delatycki, Martin B ^a,b,k   Sarsero, Joseph P ^a,b  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF MINNESOTA   (United States)

ⁱ UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^j EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k AUSTIN HEALTH   (Australia)

^l FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^m PETER MACCALLUM CANCER CENTRE   (Australia)

ⁿ MONASH UNIVERSITY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FRATAXIN; GENOMIC DNA; MESSENGER RNA; RESTRICTION ENDONUCLEASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CHEEK MUCOSA; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CPG ISLAND; DISEASE DURATION; DISEASE SEVERITY; DNA FLANKING REGION; DNA METHYLATION; FEMALE; FRIEDREICH ATAXIA; FRIEDREICH ATAXIA RATING SCALE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; ONSET AGE; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; TRINUCLEOTIDE REPEAT;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CHILD; DISEASE PROGRESSION; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; FRIEDREICH ATAXIA; GENETIC MARKERS; HUMANS; IRON-BINDING PROTEINS; MALE; MIDDLE AGED; REPETITIVE SEQUENCES, NUCLEIC ACID; TRINUCLEOTIDE REPEAT EXPANSION; YOUNG ADULT;

EID: 84857045643     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22671     Document Type: Article

References (53)

1. Bird A,. Perceptions of epigenetics. Nature 2007; 447: 396-398.
2. Urdinguio RG, Sanchez-Mut JV, Esteller M,. Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. Lancet Neurol 2009; 8: 1056-1072.
3. Delatycki MB, Williamson R, Forrest SM,. Friedreich ataxia: an overview. J Med Genet 2000; 37: 1-8.
4. De Biase I, Rasmussen A, Endres D, et al. Progressive GAA expansions in dorsal root ganglia of Friedreich's ataxia patients. Ann Neurol 2007; 61: 55-60.
5. Harding AE,. Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 1981; 104: 589-620.
6. Schulz JB, Boesch S, Burk K, et al. Diagnosis and treatment of Friedreich ataxia: a European perspective. Nat Rev Neurol 2009; 5: 222-234.
7. Tsou AY, Paulsen EK, Lagedrost SJ, et al. Mortality in Friedreich ataxia. J Neurol Sci 2011; 307: 46-49.
8. Cossee M, Durr A, Schmitt M, et al. Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol 1999; 45: 200-206.
9. Rouault TA, Tong WH,. Iron-sulfur cluster biogenesis and human disease. Trends Genet 2008; 24: 398-407.
10. Santos R, Lefevre S, Sliwa D, et al. Friedreich ataxia: molecular mechanisms, redox considerations, and therapeutic opportunities. Antioxid Redox Signal 2010; 13: 651-690.
11. Huang ML, Becker EM, Whitnall M, et al. Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant. Proc Natl Acad Sci U S A 2009; 106: 16381-16386.
12. Filla A, De Michele G, Cavalcanti F, et al. The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am J Hum Genet 1996; 59: 554-560.
13. Lamont P, Davis M, Wood N,. Identification and sizing of the GAA trinucleotide repeat expansion of Friedreich's ataxia in 56 patients. Clinical and genetic correlates. Brain 1997; 120: 673-680.
14. Santoro L, De Michele G, Perretti A, et al. Relation between trinucleotide GAA repeat length and sensory neuropathy in Friedreich's ataxia. J Neurol Neurosurg Psychiatry 1999; 66: 93-96.
15. Bit-Avragim N, Perrot A, Schols L, et al. The GAA repeat expansion in intron 1 of the frataxin gene is related to the severity of cardiac manifestation in patients with Friedreich's ataxia. J Mol Med (Berl) 2001; 78: 626-632.
16. Bidichandani SI, Ashizawa T, Patel PI,. The GAA triplet-repeat expansion in Friedreich ataxia interferes with transcription and may be associated with an unusual DNA structure. Am J Hum Genet 1998; 62: 111-121.
17. Pianese L, Turano M, Lo Casale MS, et al. Real time PCR quantification of frataxin mRNA in the peripheral blood leucocytes of Friedreich ataxia patients and carriers. J Neurol Neurosurg Psychiatry 2004; 75: 1061-1063.
18. Willis JH, Isaya G, Gakh O, et al. Lateral-flow immunoassay for the frataxin protein in Friedreich's ataxia patients and carriers. Mol Genet Metab 2008; 94: 491-497.
19. Deutsch EC, Santani AB, Perlman SL, et al. A rapid, noninvasive immunoassay for frataxin: utility in assessment of Friedreich ataxia. Mol Genet Metab 2010; 101: 238-245.
20. Saveliev A, Everett C, Sharpe T, et al. DNA triplet repeats mediate heterochromatin-protein-1-sensitive variegated gene silencing. Nature 2003; 422: 909-913.
21. Greene E, Mahishi L, Entezam A, et al. Repeat-induced epigenetic changes in intron 1 of the frataxin gene and its consequences in Friedreich ataxia. Nucleic Acids Res 2007; 35: 3383-3390.
22. Soragni E, Herman D, Dent SY, et al. Long intronic GAA*TTC repeats induce epigenetic changes and reporter gene silencing in a molecular model of Friedreich ataxia. Nucleic Acids Res 2008; 36: 6056-6065.
23. Al-Mahdawi S, Pinto RM, Ismail O, et al. The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues. Hum Mol Genet 2008; 17: 735-746.
24. Herman D, Jenssen K, Burnett R, et al. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol 2006; 2: 551-558.
25. Rai M, Soragni E, Jenssen K, et al. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS One 2008; 3: e1958.
26. Castaldo I, Pinelli M, Monticelli A, et al. DNA methylation in intron 1 of the frataxin gene is related to GAA repeat length and age of onset in Friedreich ataxia patients. J Med Genet 2008; 45: 808-812.
27. Lim F, Palomo GM, Mauritz C, et al. Functional recovery in a Friedreich's ataxia mouse model by frataxin gene transfer using an HSV-1 amplicon vector. Mol Ther 2007; 15: 1072-1078.
28. Gomez-Sebastian S, Gimenez-Cassina A, Diaz-Nido J, et al. Infectious delivery and expression of a 135 kb human FRDA genomic DNA locus complements Friedreich's ataxia deficiency in human cells. Mol Ther 2007; 15: 248-254.
29. Kearney M, Orrell RW, Fahey M, Pandolfo M,. Antioxidants and other pharmacological treatments for Friedreich ataxia. Cochrane Database Syst Rev 2009 (4): CD007791.
30. Lynch DR, Perlman SL, Meier T,. A phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich ataxia. Arch Neurol 2010; 67: 941-947.
31. Subramony SH, May W, Lynch D, et al. Measuring Friedreich ataxia: interrater reliability of a neurologic rating scale. Neurology 2005; 64: 1261-1262.
32. Holloway TP, Rowley SM, Delatycki MB, Sarsero JP,. Detection of interruptions in the GAA trinucleotide repeat expansion in the FXN gene of Friedreich ataxia. Biotechniques 2011; 50: 182-186.
33. Ehrich M, Nelson MR, Stanssens P, et al. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A 2005; 102: 15785-15790.
34. Jollife I,. Principal component analysis. 2nd ed. New York, NY: Springer-Verlag, 2002.
35. Godler DE, Tassone F, Loesch DZ, et al. Methylation of novel markers of fragile X alleles is inversely correlated with FMRP expression and FMR1 activation ratio. Hum Mol Genet 2010; 19: 1618-1632.
36. Lopez Castel A, Nakamori M, Tome S, et al. Expanded CTG repeat demarcates a boundary for abnormal CpG methylation in myotonic dystrophy patient tissues. Hum Mol Genet 2011; 20: 1-15.
37. Pollard LM, Sharma R, Gomez M, et al. Replication-mediated instability of the GAA triplet repeat mutation in Friedreich ataxia. Nucleic Acids Res 2004; 32: 5962-5971.
38. Clark RM, De Biase I, Malykhina AP, et al. The GAA triplet-repeat is unstable in the context of the human FXN locus and displays age-dependent expansions in cerebellum and DRG in a transgenic mouse model. Hum Genet 2007; 120: 633-640.
39. Cho DH, Thienes CP, Mahoney SE, et al. Antisense transcription and heterochromatin at the DM1 CTG repeats are constrained by CTCF. Mol Cell 2005; 20: 483-489.
40. Moseley ML, Zu T, Ikeda Y, et al. Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8. Nat Genet 2006; 38: 758-769.
41. Ladd PD, Smith LE, Rabaia NA, et al. An antisense transcript spanning the CGG repeat region of FMR1 is upregulated in premutation carriers but silenced in full mutation individuals. Hum Mol Genet 2007; 16: 3174-3187.
42. De Biase I, Chutake YK, Rindler PM, Bidichandani SI,. Epigenetic silencing in Friedreich ataxia is associated with depletion of CTCF (CCCTC-binding factor) and antisense transcription. PLoS One 2009; 4: e7914.
43. Ozanne SE, Constancia M,. Mechanisms of disease: the developmental origins of disease and the role of the epigenotype. Nat Clin Pract Endocrinol Metab 2007; 3: 539-546.
44. Schar P, Fritsch O,. DNA repair and the control of DNA methylation. Prog Drug Res 2011; 67: 51-68.
45. Kumari D, Usdin K,. Chromatin remodeling in the noncoding repeat expansion diseases. J Biol Chem 2009; 284: 7413-7417.
46. Mill J, Tang T, Kaminsky Z, et al. Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am J Hum Genet 2008; 82: 696-711.
47. Kuratomi G, Iwamoto K, Bundo M, et al. Aberrant DNA methylation associated with bipolar disorder identified from discordant monozygotic twins. Mol Psychiatry 2008; 13: 429-441.
48. Philibert R, Madan A, Andersen A, et al. Serotonin transporter mRNA levels are associated with the methylation of an upstream CpG island. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 101-105.
49. Katari S, Turan N, Bibikova M, et al. DNA methylation and gene expression differences in children conceived in vitro or in vivo. Hum Mol Genet 2009; 18: 3769-3778.
50. Steegers-Theunissen RP, Obermann-Borst SA, Kremer D, et al. Periconceptional maternal folic acid use of 400 microg per day is related to increased methylation of the IGF2 gene in the very young child. PLoS One 2009; 4: e7845.
51. Xu C, Soragni E, Chou CJ, et al. Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencing. Chem Biol 2009; 16: 980-989.
52. Lim F, Diaz-Nido J,. Gene therapy approaches to ataxias. Curr Gene Ther 2009; 9: 1-8.
53. Liu J, Verma PJ, Evans-Galea MV, et al. Generation of induced pluripotent stem cell lines from Friedreich ataxia patients. Stem Cell Rev 2011; 7: 703-713.